Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

Second Nature

Second Nature Raises $22M in Series B

Tel Aviv, IsraelOctober 16, 20252 min read
Employees
100+

Second Nature Raises $22M in Series B


Second Nature has successfully raised $22M in a Series B at a $80M valuation led by Owl Ventures, Hearst Ventures, Square Peg.


Company Overview


Second Nature is a SaaS company headquartered in Tel Aviv, Israel, founded in 2018 with 100+ employees.


AI-powered sales training and coaching platform using conversational AI


Fundraising Details


  • Amount Raised: $22M
  • Round Type: Series B
  • Valuation: $80M
  • Date: 2025-10-16
  • Investors: Owl Ventures, Hearst Ventures, Square Peg

About Second Nature


AI-powered sales training and coaching platform using conversational AI The company is positioned in the SaaS sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: Tel Aviv, Israel
  • Founded: 2018
  • Team Size: 100+
  • Industry: SaaS

What This Means


This funding round demonstrates strong investor confidence in Second Nature's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The SaaS sector continues to attract significant investment as companies innovate to meet evolving market demands. Second Nature's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $80M valuation marks an important milestone for Second Nature, positioning the company among notable players in the SaaS industry.


Looking Ahead


With this new capital, Second Nature is well-positioned to execute on its growth strategy and continue building innovative solutions in the SaaS space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2025-10-16. For more information about Second Nature, visit their headquarters at Tel Aviv, Israel.

Company Info

Headquarters
Tel Aviv, Israel
Founded
2018
Team Size
100+

Topics

Fundraising(2912)SaaS(832)Series B(306)Second Nature

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free